摘要
目的探讨德谷门冬双胰岛素在糖尿病治疗中的临床效果。方法回顾性选取2023年11月—2024年11月长春中医药大学附属第四临床医院(长春市人民医院)收治的104例2型糖尿病患者的临床资料,根据不同治疗方法为对照组和研究组,各52例。对照组接受常规胰岛素治疗,研究组接受德谷门冬双胰岛素治疗。对比两组的血糖指标水平、胰岛素抵抗指数和不良反应。结果研究组治疗后的空腹血糖、餐后2 h血糖、糖化血红蛋白和胰岛素抵抗指数均低于对照组,差异均有统计学意义(P均<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论德谷门冬双胰岛素治疗2型糖尿病的效果较好,能有效控制血糖水平,且不良反应较少。
Objective To explore the clinical effect of insulin degludec aspart in the treatment of diabetes mellitus.Methods From November 2023 to November 2024,the clinical data of 104 patients with type 2 diabetes mellitus admitted to the Fourth Affiliated Hospital of Changchun University of Traditional Chinese Medicine(Changchun People's Hospital)were retrospectively selected.According to different treatment methods,they were divided into control group and study group,52 cases in each group.The control group received conventional insulin therapy,and the study group was treated with insulin degludec aspart.The blood glucose level,insulin resistance index and adverse reactions of the two groups were compared.Results After treatment,the fasting plasma glucose,2-hour postprandial plasma glucose,glycated hemoglobin A1c and insulin resistance index in the study group were lower than those in the control group,and the differences were statistically significant(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The effect of insulin degludec aspart in the treatment of type 2 diabetes mellitus is better,which can effectively control the blood glucose level and has fewer adverse reactions.
作者
王雪
崔磊
马利新
WANG Xue;CUI Lei;MA Lixin(Department of Digestive Endocrinology Ⅱ,the Fourth Affiliated Hospital of Changchun University of Traditional Chinese Medicine(Changchun People's Hospital),Changchun 130000,Jilin,China)
出处
《糖尿病新世界》
2025年第21期101-104,共4页
Diabetes New World
关键词
德谷门冬双胰岛素
2型糖尿病
糖化血红蛋白
胰岛素抵抗
Insulin degludec aspart
Type 2 diabetes mellitus
Glycated hemoglobin A1c
Insulin resistance
